Trinity compound research profile
Mazdutide
Mazdutide is a lab-made peptide (chain of amino acid building blocks) that copies and extends a natural gut hormone called oxyntomodulin, which your...
Research overview
Mazdutide is a lab-made peptide (chain of amino acid building blocks) that copies and extends a natural gut hormone called oxyntomodulin, which your intestines release after eating. It was developed by the company Innovent Biologics together with Eli Lilly, and is sold in China under the brand name Xinermei (IUPHAR/BPS Guide to Pharmacology; Drugs 2025).
Mechanism under study
Mazdutide is a "dual" hormone mimic — it activates two different hormone docking stations (receptors) at once: one for GLP-1 (which controls blood sugar, slows digestion, and reduces appetite — similar to liraglutide above) and one for glucagon (a hormone that can help the body burn more energy and mobilize fat stored in the liver). By hitting both targets, it's designed to combine appetite suppression with a metabolism boost.
Human evidence summary
In a large Chinese clinical trial with 610 people over 48 weeks, mazdutide led to significant weight loss: at week 32, people lost about 10-12.5% of body weight (versus almost no change with placebo), and by week 48, some groups lost around 11-14% of body weight, with very few people quitting the trial due to side effects (NEJM 2025). It's also being studied for fatty liver disease, sleep apnea, and alcohol use disorder, though those trials are still ongoing.
Preclinical evidence summary
The provided source data doesn't detail specific animal studies for mazdutide — its evidence base focuses on the strong human clinical trial results described above.
Source material
Use the linked publications and records to evaluate study design, population, limitations, and relevance.